Epinastine: Topical ophthalmic second generation antihistamine without significant systemic side effects

Expert Opinion on Drug Metabolism and Toxicology

Volumn 5, Issue 9, 2009, Pages 1135-1140

  Pradhan, Shilpi ^c   Abhishek, Kumar ^b   Mah, Francis ^a  

^a University of Pittsburgh School of Medicine   (United States)

^b ALLEGHENY GENERAL HOSPITAL   (United States)

^c NONE

Author keywords

Allergic conjunctivitis; Epinastine; Ocular allergy

Indexed keywords

AZELASTINE; EPINASTINE; KETOTIFEN; OLOPATADINE;

ALLERGIC CONJUNCTIVITIS; BURNING SENSATION; CLINICAL TRIAL; DRUG ABSORPTION; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PHARYNGITIS; PRURITUS; REVIEW; RHINITIS; SINUSITIS;

CLINICAL TRIALS AS TOPIC; CONJUNCTIVITIS, ALLERGIC; DIBENZAZEPINES; HISTAMINE ANTAGONISTS; HUMANS; IMIDAZOLES;

EID: 70249108858     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250903117284     Document Type: Review

References (48)

1. Bielory L. Allergic and immunologic disorders of the eye: part II. Ocular allergy. J Allergy Clin Immunol 2000;106(6):1019-1032 (Pubitemid 32006253)
2. Bielory L, Friedlaender MH. Allergic conjunctivitis. Immunol Allergy Clin North Am 2008;28(1):43-58
3. Bielory L. Ocular Allergy Overview. Immunol Allergy Clin North Am 2008;29:1-23
4. Leonardi A, Motterle L, Bortolotti M. Allergy and the eye. Clin Exp Immunol 2008;153(Suppl 1):17-21
5. Bachert C. Histamine - A major role in allergy? Clin Exp Allergy 1998;28(Suppl 6):15-19
6. Bielory L, Ghafoor S. Histamine receptors and the conjunctiva. Curr Opin Allergy Clin Immunol 2005;5(5):437-440
7. Bielory L. Ocular allergy treatment. Immunol Allergy Clin North Am 2008;28(1):189-224
8. Meltzer EO. The prevalence and medical and economic impact of allergic rhinitis in the United States. J Allergy Clin Immunol 1997;99:S805-28
9. Marshall PS, Colon EA. Effects of allergy season on mood and cognitive function. Ann Allergy 1993;71:251-258
10. Malone DC, Lawson KA, Smith DH, et al. A cost of illness study of allergic rhinitis in the United States. J Allergy Clin Immunol 1997;99:22-27 (Pubitemid 27074893)
11. Oppenheimer JJ, Casale TB. Next generation antihistamines: therapeutic rationale, accomplishments, and advances. Expert Opin Investig Drugs 2002;11(6):807-817
12. Lanier BQ, Gross RD, Marks BB, et al. Olopatadine ophthalmic solution adjunctive to loratadine compared with loratadine alone in patients with active seasonal allergic conjunctivitis symptoms. Ann Allergy Asthma Immunol 2001;86(6):641-648
13. Friedlaender MH. Epinastine in the management of ocular allergic disease. Int Ophthalmol Clin 2006;46(4):85-86 (Pubitemid 44632211)
14. Fügner A, Bechtel WD, Kuhn FJ, Mierau J. In vitro and in vivo studies of the non-sedating antihistamine epinastine. Arzneimittelforschung 1988;38(10):1446-1453
15. Fügner A, Meissner C. Accumulation of granulocytes in the lung and skin of guinea pigs. Inhibition by the anti-H1 antiallergic agent epinastine. Arzneimittelforschung 1994;44(12):1338-1342
16. Inagaki N, Nagao M, Nakamura N, et al. Evaluation of anti-scratch properties of oxatomide and epinastine in mice. Eur J Pharmacol 2000;400(1):73-79 (Pubitemid 30412111)
17. Schilling JC, Adamus WS, Kuthan H. Antihistaminic activity and side effect profile of epinastine and terfenadine in healthy volunteers. Int J Clin Pharmacol Ther Toxicol 1990;28(12):493-497
18. Leroy T, van Neste D. Dermal objective pharmacodynamic profile of cetirizine and epinastine: two controlled, randomised, double-blind, crossover studies. Int J Clin Pract 2002;56(8):568-573 (Pubitemid 35256388)
19. Grant JA, Danielson L, Rihoux JP, DeVos C. A double-blind, single-dose, crossover comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadine, and loratadine versus placebo: suppression of histamine-induced wheal and flare response for 24 h in healthy male subjects. Allergy 1999;54(7):700-707
20. Mita H, Shida T. Comparison of anti-allergic activities of the histamine H1 receptor antagonists epinastine, ketotifen and oxatomide in human leukocytes. Arzneimittelforschung 1995;45(1):36-40
21. Amon U, Gibbs BF, Buss G, Nitschke M. In vitro investigations with the histamine H1 receptor antagonist, epinastine (WAL 801 CL), on isolated human allergic effector cells. Inflamm Res 2000;49(3):112-116
22. Hanashiro K, Sunagawa M, Tokeshi Y, et al. Antiallergic drugs, azelastine hydrochloride and epinastine hydrochloride, inhibit ongoing IgE secretion of rat IgE-producing hybridoma FE-3 cells. Eur J Pharmacol 2006;547(1-3):174-183 (Pubitemid 44373904)
23. Kamei C, Akagi M, Mio M, et al. Antiallergic effect of epinastine (WAL 801 CL) on immediate hypersensitivity reactions: (I). Elucidation of the mechanism for histamine release inhibition. Immunopharmacol Immunotoxicol 1991;14(1-2):191-205
24. Misawa M, Kanai Y. Effect of the new antiallergic drug epinastine on chemical mediator induced bronchoconstrictions in guinea pigs. Arzneimittelforschung 1991;41(11):1145-1149
25. Kamei C, Mio M, Kitazumi K, et al. Antiallergic effect of epinastine (WAL 801 CL) on immediate hypersensitivity reactions: (II). Antagonistic effect of epinastine on chemical mediators, mainly antihistaminic and anti-PAF effects. Immunopharmacol Immunotoxicol 1992;14(1-2):207-218
26. Kohyama T, Takizawa H, Akiyama N, et al. A novel antiallergic drug epinastine inhibits IL-8 release from human eosinophils. Biochem Biophys Res Commun 1997;230(1):125-128 (Pubitemid 27210256)
27. Matsukura M, Yajima A, Yamazaki F, et al. Epinastine inhibits eosinophil chemotaxis and adhesion molecules in atopic dermatitis. Skin Pharmacol Appl Skin Physiol 2003;16(6):405-410 (Pubitemid 37256076)
28. Kanai K, Asano K, Hisamitsu T, Suzaki H. Suppressive activity of epinastine hydrochloride on TARC production from human peripheral blood CD4+ T cells in-vitro. J Pharm Pharmacol 2005;57(8):1027-1036 (Pubitemid 41039838)
29. Kanai K, Asano K, Watanabe S, et al. Epinastine hydrochloride antagonism against interleukin-4-mediated T cell cytokine imbalance in vitro. Int Arch Allergy Immunol 2006;140(1):43-52
30. Galatowicz G, Ajayi Y, Stern ME, Calder VL. Ocular anti-allergic compounds selectively inhibit human mast cell cytokines in vitro and conjunctival cell infiltration in vivo. Clin Exp Allergy 2007;37(11):1648-1656 (Pubitemid 47609843)
31. Ohtani H, Kotaki H, Sawada Y, Iga T. A comparative pharmacokineticpharmacodynamic study of the electrocardiographic effects of epinastine and terfenadine in rats. J Pharm Pharmacol 1997;49(4):458-462 (Pubitemid 27207704)
32. Kishimoto W, Hiroi T, Sakai K, et al. Metabolism of epinastine, a histamine H1 receptor antagonist, in human liver microsomes in comparison with that of terfenadine. Res Commun Mol Pathol Pharmacol 1997;98(3):273-292 (Pubitemid 28168546)
33. Yanai K, Ryu JH, Watanabe T, et al. Positron emission tomographic study of central histamine H1-receptor occupancy in human subjects treated with epinastine, a second-generation antihistamine. Methods Find Exp Clin Pharmacol 1995;17(Suppl C):64-69 (Pubitemid 26022895)
34. Sarashina A, Tatami S, Yamamura N, et al. Population pharmacokinetics of epinastine, a histamine H1 receptor antagonist, in adults and children. Br J Clin Pharmacol 2005;59(1):43-53 (Pubitemid 40040095)
35. Toyoda M, Nakamura M, Nakagawa H. Distribution to the skin of epinastine hydrochloride in atopic dermatitis patients. Eur J Dermatol 2007;17(1):33-36 (Pubitemid 46383218)
36. Ogiso T, Kasutani M, Tanaka H, et al. Pharmacokinetics of epinastine and a possible mechanism for double peaks in oral plasma concentration profiles. Biol Pharm Bull 2001;24(7):790-794 (Pubitemid 32633487)
37. Whitcup SM, Bradford R, Lue J, et al. Efficacy and tolerability of ophthalmic epinastine: a randomized, double-masked, parallel-group, active- and vehicle-controlled environmental trial in patients with seasonal allergic conjunctivitis. Clin Ther 2004;26(1):29-34 (Pubitemid 38241520)
38. Abelson MB, Gomes P, Crampton HJ, et al. Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis. Clin Ther 2004;26(1):35-47 (Pubitemid 38241521)
39. Monson BK, Rothman JS, Raizman MB. Efficacy of epinastine ophthalmic solution for post-exposure treatment of signs and symptoms of allergic conjunctivitis in cat-sensitive subjects. Presented at Annual Meeting of the American College of Allergy, Asthma, and Immunology, November 12-17, 2004, Boston, MA
40. Lanier BQ, Finegold I, D'Arienzo P, et al. Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model. Curr Med Res Opin 2004;20(8):1227-1233 (Pubitemid 39120787)
41. Finegold I, Granet DB, D'Arienzo PA, Epstein AB. Efficacy and response with olopatadine versus epinastine in ocular allergic symptoms: a post hoc analysis of data from a conjunctival allergen challenge study. Clin Ther 2006;28(10):1630-1638 (Pubitemid 44848366)
42. Mah FS, Rosenwasser LJ, Townsend WD, et al. Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge. Curr Med Res Opin 2007;23(6):1445-1452
43. Chachin M, Katayama Y, Yamada M, et al. Epinastine, a nonsedating histamine H1 receptor antagonist, has a negligible effect on HERG channel. Eur J Pharmacol 1999;374(3):457-460 (Pubitemid 29313458)
44. Tasaka K, Kamei C, Nakamura S. Inhibitory effect of epinastine on bronchoconstriction induced by histamine, platelet activating factor and serotonin in guinea pigs and rats. Arzneimittelforschung 1994;44(3):327-329 (Pubitemid 24102558)
45. Trattler WB, Luchs J, Majmudar P. Elestat (epinastine HCl ophthalmic solution 0.05%) as a therapeutic for allergic conjunctivitis. Int Ophthalmol Clin 2006;46(4):87-99 (Pubitemid 44632212)
46. Ousler GW 3rd, Workman DA, Torkildsen GL. An open-label, investigator-masked, crossover study of the ocular drying effects of two antihistamines, topical epinastine and systemic loratadine, in adult volunteers with seasonal allergic conjunctivitis. Clin Ther 2007;29(4):611-616
47. Torkildsen GL, Ousler GW, Gomes P. Ocular comfort and drying effects of three topical antihistamine/mast cell stabilizers in adults with allergic conjunctivitis: a randomized, double-masked crossover study. Clin Ther 2008;30(7):1264-1271
48. Villareal AL, Farley W, Pflugfelder SC. Effect of topical ophthalmic epinastine and olopatadine on tear volume in mice. Eye & Contact Lens. Sci Clin Pract 2006;32(6):272-276 (Pubitemid 44747200)